Gielsdorf W, Schubert K
J Clin Chem Clin Biochem. 1981 Jul;19(7):485-90.
After administration of therapeutic doses of doxylamine, the unchanged drug(I) and five degradation products were detected in human urine; their chemical structures are discussed and - to some extent - confirmed by synthesis. The results show that biotransformation of doxylamine in man takes place by the following routes: successive dealkylations at the nitrogen atom, giving N-demethyl-doxylamine(II) and N.N-didemethyl-doxylamine(II); cleavage at the benzhydrylether-function, resulting in the formation of 1-phenyl-1-(2-pyridyl)-ethanol(V), 1-phenyl-1-(2-pyridyl)-ethane(VI) and 1-phenyl-1-(2-pyridyl)-ethene(VII). VI and VII may be artefacts. Identification of an additional degradation product(=IV) was not possible, because the isolated quantities were too small. The analytical properties (hydrolysis!) of the pure substance and free base are thoroughly discussed, as well as the role of Chemical Ionization Mass Spectrometry with various reagent gases for the examination of biological extracts.
给予治疗剂量的多西拉敏后,在人尿中检测到未变化的药物(I)和五种降解产物;讨论了它们的化学结构,并通过合成在一定程度上得到了证实。结果表明,多西拉敏在人体内的生物转化通过以下途径进行:氮原子上的连续脱烷基化,生成N-去甲基多西拉敏(II)和N,N-二去甲基多西拉敏(III);二苯甲基醚官能团处的裂解,导致形成1-苯基-1-(2-吡啶基)-乙醇(V)、1-苯基-1-(2-吡啶基)-乙烷(VI)和1-苯基-1-(2-吡啶基)-乙烯(VII)。VI和VII可能是人工产物。由于分离得到的量太小,无法鉴定出另一种降解产物(=IV)。详细讨论了纯物质和游离碱的分析性质(水解!),以及使用各种反应气体的化学电离质谱法在生物提取物检测中的作用。